Skip to main content
Home Home

User account menu

Log in

Main navigation

  • Home
  • Topics
    • Antimicrobials
    • Asthma
    • Biological medicines
    • COVID-19 medicines
    • Cardiovascular disease
    • Equity
    • Focus medicines
    • Gout
    • Menopause
    • Type 2 diabetes
    • Youth mental health
  • Resources
    • All education/search
    • Brand changes
    • Clinical articles
    • HAH Bulletins
    • Podcasts
    • Recorded webinars
    • Reflect & audit activities
    • Resource hubs
    • Videos
  • EPiC dashboard
    • Go to EPiC
    • Join EPiC
    • EPiC FAQ
    • EPiC Demo
    • About EPiC
    • Book EPiC training
  • News
    • Events
    • That's Interesting
    • From The Team
    • Coming Soon

Education

  1. Home
  2. Search

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

Bulletin #8

Beyond unreasonable gout

1 minute to Read

The jury is in – usual gout care isn’t working well, especially for Māori and Pacific peoples, who are disproportionately affected by this common disorder.

What potential tools are readily available to reduce gout harm? Specific clinician actions!  

Read the bulletin to find out more.

Contributor
He Ako Hiringa
26 October 2021
  • HAH Bulletins
  • Gout
Gout resource repository

Gout resource repository

Looking for up-to-date information on gout? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
18 October 2021
  • Gout
Dulaglutide Questions and Answers

Dulaglutide and empagliflozin: Your questions answered (2)

45 minutes to Delve

Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.

Contributor
Dr Ryan Paul (Ngāti Maru)
13 October 2021
  • Diabetes
Initiating new medicines - with Prof. Keith Petrie

Episode One: Initiating new medicines (part 1)

17 minutes to Listen

Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know. 

Contributor
Professor Keith Petrie
11 October 2021
  • Podcast
  • Reflect & audit activities
Gout Image Test

Beyond medicines for gout

21 minutes to Read + 24 minutes to Delve

Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.

30 September 2021
  • Gout
  • Clinical article
Bulletin #7

Biosimilars: A promising new era

1 minute to Read

Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.  

As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
27 September 2021
  • HAH Bulletins
  • Biological medicines
Parkinson's Disease

Selegiline is no longer available: What does this mean for your patients?

8 minutes to Read

Since originally publishing this article in September 2021, selegiline has been discontinued and supplies have been depleted. Rasagiline is now the only funded MAO-B inhibitor available in New Zealand.

This resource provides advice on prescribing and supplying rasagiline, which is currently funded but not yet approved by Medsafe.

Contributor
He Ako Hiringa
14 September 2021
  • Selegiline rasagiline
  • Clinical article
  • Focus medicine

Dulaglutide: the long-awaited new agent to treat type 2 diabetes

78 minutes to Watch

In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.

Contributor
Dr Ryan Paul (Ngāti Maru)
2 September 2021
  • Diabetes
  • Recorded webinars

Can you say dulaglutide?

Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.

Contributor
He Ako Hiringa
30 August 2021
  • Videos
  • Diabetes
Image of a flowchart

Initiating treatment with empagliflozin: Algorithms, notes and talking points

15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul (Ngāti Maru)
24 August 2021
  • Diabetes
  • Equity
  • Clinical article

Heart failure therapy: from past to present

60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Contributor
Dr Raewyn Fisher
24 August 2021
  • CVD
  • Recorded webinars
Bulletin #6

Considering the new T2D agents

1 minute to Read

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,1 choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin (updated July 2022) to find out more.

Contributor
He Ako Hiringa
17 August 2021
  • HAH Bulletins
  • Diabetes

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next › Next page
  • Last » Last page
Home Home

Contact Us

PO Box 31905, Milford Auckland NZ, 0741

Support

09 488 4286

admin@akohiringa.co.nz

(9-5pm Mon-Fri)

Contact us

About us

Terms & Policies

  • Conditions for Use
  • Privacy Policy

Supported by

Pharmac

© Matui Limited. All rights reserved.

Developed by Matui Limited and brought to life by Communica.